Biotech Investors in Europe

AltamarCAM Partners is an independent, partner-led private asset manager founded in 2004 and headquartered in Madrid, Spain. The firm specializes in providing institutional investors—including insurance companies, pension funds, and financial institutions—as well as high-net-worth individuals, with access to global alternative investments across private equity, venture capital, life sciences, real assets (real estate and infrastructure), and private debt/credit. Their investment strategies encompass primaries, secondaries, and co-investments, tailored to meet diverse client needs. With over €20.8 billion in assets under management, AltamarCAM operates through a network of specialized entities, including Altamar Private Equity, Altan Capital, and Altamar Advisory Partners. These subsidiaries enable the firm to offer a comprehensive suite of services, from fund management to independent financial advisory and merchant banking. The firm's global presence includes offices in Madrid, Barcelona, Munich, Cologne, London, New York, and Santiago de Chile, supported by a team of more than 350 professionals. AltamarCAM is committed to delivering long-term value through a disciplined investment approach and a strong focus on environmental, social, and governance (ESG) principles. Their diversified portfolio and strategic partnerships, such as the recent collaboration with Mirabaud to launch an evergreen semi-liquid private equity strategy, underscore their dedication to innovation and client-centric solutions in the private markets.

Asabys Partners is a Barcelona-based venture capital firm focused on investing in highly innovative companies within the healthcare and life sciences sectors. Founded in 2018, Asabys aims to support disruptive technologies and transformational therapies by backing entrepreneurs developing novel solutions in biotech, medtech, diagnostics, and digital health. The firm leverages deep sectoral expertise and a strong scientific network to identify and nurture promising startups from early to growth stages.The firm’s investment philosophy emphasizes value creation through active involvement. Asabys works closely with portfolio companies by providing strategic guidance, operational support, and access to a global network of industry experts and partners. Its team is composed of experienced investors, healthcare professionals, and scientists, enabling a multidisciplinary approach to sourcing and scaling impactful innovations.With a geographic focus on Europe and Israel, Asabys seeks companies with global potential and strong IP positions. Backed by prominent institutional investors, the firm manages the Sabadell Asabys Health Innovation Fund and continues to expand its presence in the European venture ecosystem. Asabys is committed to contributing to the advancement of healthcare by supporting the next generation of medical breakthroughs.

Backed VC is a London-based venture capital firm founded with a mission to empower the next generation of European entrepreneurs. The firm prides itself on taking a founder-first approach, backing ambitious startups at the earliest stages and providing tailored support beyond capital. With a strong belief in personal conviction and long-term partnerships, Backed VC actively works alongside the companies it invests in to help them scale and succeed.The firm focuses on pre-seed and seed-stage investments, targeting disruptive technology companies across sectors such as AI, biotech, fintech, and consumer. Backed VC is known for its deep involvement in the founder community and emphasizes cultural fit and alignment with the vision of the startups it supports. It also helps founders build their teams, access global networks, and navigate early operational challenges.With a portfolio that spans dozens of high-potential startups across Europe, Backed VC has quickly built a reputation as a go-to investor for early-stage innovation. The team comprises diverse professionals with backgrounds in entrepreneurship, product, and venture, enabling a holistic approach to startup development. The firm is committed to reshaping the future of venture capital by championing transparency, empathy, and founder empowerment.

The Brain Tumor Investment Fund (BTIF) is a venture philanthropy fund and subsidiary of the National Brain Tumor Society (NBTS), leveraging over 30 years of NBTS’s expertise to support the development of innovative treatments for brain tumors. BTIF invests philanthropic capital into biotechnology, pharmaceutical, and medical device companies focused on brain tumor diagnostics and therapeutics, aiming to bridge the gap between academic discovery and commercial product development. BTIF acts as a convener and catalyst for private sector investment in the brain tumor space, fostering a robust and diverse market for drug development. The fund targets early-stage companies (pre-seed to Series A) with promising brain tumor assets, including small molecules, biologics, gene and cell therapies, vaccines, and medical devices. BTIF also provides portfolio companies with access to expert networks in neuro-oncology, regulatory affairs, and manufacturing to accelerate development. Led by a distinguished team with deep experience in brain tumor research, drug development, and investment, BTIF is headquartered in Newton, Massachusetts, USA. The fund focuses on creating new survival and quality-of-life treatment opportunities for brain tumor patients globally, investing primarily in companies based in the USA, Canada, Europe, and Israel.

Clave Capital, founded circa 2002 and headquartered in Pamplona, Spain, is a venture capital and tech‑transfer investment firm with 20+ years of experience and over 90 investments across industrial SMEs, healthtech, energy, agri‑food and biotech sectors. The firm manages the **Clave Innohealth Fund** (≈€50 M first close, targeting €80 M) focused on early-stage health innovation—eHealth, medtech, biotech, nutrition—backed by CDTI/Innviierte and private investors. Typical checks range from €500K to €1M with follow-ons up to €3 M. Clave operates from its Pamplona headquarters and maintains a regional Valencia office. With a tight-knit team (~20 professionals), Clave combines financial investment with operational involvement, partnering closely with founders and university research centers to scale innovation-driven SMEs.

Curie Capital, founded in 2018 and headquartered in Amsterdam, Netherlands, is a venture capital firm specializing in early-stage investments within the life sciences sector. The firm focuses on Seed and Series A rounds, targeting innovative biotechnology, pharmaceutical, and medical technology companies, particularly those developing therapeutics, diagnostics, or class IIb and III medical devices.Curie Capital not only provides capital but also strategic support, leveraging its extensive network and experience to help build successful companies. Operating primarily from its current fund, Curie Capital 3, the firm complies with RVO seed capital regulations, investing exclusively in companies headquartered in the Netherlands that have not raised more than €3.5 million in equity or convertible loans.With the anticipated launch of Curie Capital 4 in 2025, the firm plans to broaden its investment scope to include high-impact life sciences companies across Europe, expanding beyond its Dutch-centric focus. The Curie Capital team consists of life science experts and business analysts who actively guide portfolio companies through research and development phases. The firm typically acts as a lead investor and syndicates investments with experienced co-investors.Notable portfolio companies include TargED Biopharmaceuticals, Citryll, and Avidicure, reflecting Curie Capital’s commitment to advancing cutting-edge medical innovations.

Forbion is a venture capital firm that specializes in the life sciences sector, with a particular focus on biotechnology and pharmaceuticals. Established in 2009, the firm has built a strong reputation for its investments in innovative life sciences companies. Forbion is dedicated to supporting the development of new therapeutics and technologies that can significantly impact healthcare outcomes.The firm operates primarily in Europe and North America, targeting regions that are known for their advancements in life sciences. Forbion's investment strategy emphasizes the importance of fostering innovation in healthcare, and it aims to partner with companies that are at the forefront of scientific research and development.With offices located in Amsterdam, Munich, and San Francisco, Forbion is well-positioned to leverage its extensive network and expertise in the life sciences industry. The firm is recognized for its commitment to nurturing the growth of its portfolio companies, providing not only financial support but also strategic guidance to help them navigate the complexities of the healthcare landscape.

Kleiner Perkins, founded in 1972 by Eugene Kleiner and Tom Perkins, is a renowned venture capital firm based in Menlo Park, California. With a legacy of backing pioneering companies like Amazon, Google, and Genentech, the firm has been instrumental in shaping the technology landscape. Over the decades, Kleiner Perkins has invested in over 900 ventures, focusing on early-stage and growth-stage companies that drive innovation across various sectors. The firm's investment strategy encompasses a broad range of industries, including technology, healthcare, life sciences, and sustainability. Kleiner Perkins is known for its hands-on approach, partnering closely with entrepreneurs to provide not only capital but also strategic guidance and operational support. This collaborative model has led to numerous successful exits, including IPOs and acquisitions, solidifying its reputation as a top-tier venture capital firm. With offices in Menlo Park, San Francisco, and Shanghai, Kleiner Perkins maintains a global presence to support its diverse portfolio. The firm's commitment to fostering groundbreaking ideas and its track record of successful investments continue to attract visionary founders seeking to make a significant impact in their respective industries.

Monograph Capital is an investment firm focused on the life sciences sector, specifically targeting companies that create new or improved therapeutics, diagnostics, and related technology-enabled business services. The firm aims to enhance healthcare outcomes through its investments. With primary offices located in London, San Francisco, and Dallas-Fort Worth, Monograph Capital bridges opportunities across North America, the United Kingdom, and Europe. This geographical presence allows the firm to leverage deep experience, relationships, and capabilities to help life sciences companies scale effectively. The Monograph team comprises individuals with decades of experience in biomedical research and clinical medicine, complemented by over 55 years of cumulative investing experience in the healthcare industry. This extensive background enables Monograph to actively contribute to the growth of nascent organizations into promising biotechnology and related life sciences businesses. Monograph Capital routinely identifies investment opportunities that have the potential to lead to transformational healthcare outcomes.

Quadrille Capital is a Paris-based investment firm focused on technology and healthcare sectors across Europe and North America. Established in 2001, Quadrille combines fund investments, direct investments in high-growth companies, and secondary transactions to deliver a flexible and diversified investment approach. The firm partners with entrepreneurs and fund managers at the forefront of innovation and disruption. Quadrille Capital operates with a strong emphasis on growth equity, targeting companies and funds in sectors such as software, IT infrastructure, digital platforms, biotechnology, and medical technology. Its hybrid investment model allows it to allocate capital efficiently across different stages of company growth while maintaining exposure to a broad network of market leaders. The team leverages deep industry knowledge and global relationships to identify unique opportunities and create long-term value. With a proven track record and a disciplined strategy, Quadrille Capital manages institutional capital from pension funds, insurance companies, and family offices. The firm’s independent and partner-owned structure ensures alignment with its investors and portfolio companies. As technology and healthcare continue to shape the future economy, Quadrille remains focused on supporting innovation through strategic capital deployment.

Sofinnova Partners is recognized as one of the leading venture capital firms in Europe, particularly in the life sciences sector. Founded in 1972, the firm has a long history of successful investments in innovative healthcare companies.Sofinnova Partners primarily focuses on life sciences, including biotechnology, pharmaceuticals, and medical devices. The firm targets regions in Europe and North America, aiming to support companies that are at the forefront of medical innovation.The firm is structured to provide extensive support to its portfolio companies, leveraging a team of experienced professionals with deep industry knowledge. This team is dedicated to identifying and nurturing groundbreaking technologies that can transform healthcare.With a commitment to fostering innovation, Sofinnova Partners seeks to invest in companies that are poised to make significant impacts in their respective fields, ensuring that they are well-positioned for growth and success.

SV Health Investors is a global healthcare investment firm with a 30-year track record of transforming healthcare through strategic investments. Founded in 1993, the firm manages approximately $3.7 billion to $4.0 billion in historical commitments across diversified private equity and venture capital funds. Their investment focus spans biotechnology (including dementia), healthcare growth equity, and medical technology, supporting companies at all stages from early seed to growth and late-stage development.With offices in Boston and London, SV Health Investors leverages a team of over 50 experienced investment professionals and operating partners who bring deep sector expertise and healthcare industry experience. The firm emphasizes backing diverse entrepreneurs and management teams to build innovative healthcare companies that improve patient outcomes while generating shareholder value. To date, SV has invested in nearly 300 companies, with over 75 achieving successful IPOs or mergers and acquisitions.SV Health Investors’ portfolio includes companies across healthcare services, digital health, medical devices, and biotechnology sectors. Their hands-on approach combines capital with strategic guidance, helping portfolio companies advance novel treatments and technologies that address unmet medical needs globally. The firm is committed to fostering innovation that benefits patients and drives long-term growth in the healthcare industry.

TruVenturo GmbH is a Hamburg-based company builder and single-family office founded in 2009 by serial entrepreneur Nils Regge. The firm specializes in co-founding and scaling digital ventures, with a focus on innovative technologies and transformative business models. TruVenturo has been instrumental in launching and scaling companies like HomeToGo, Dreamlines, and Finanzcheck. Nils Regge built his wealth through a series of successful digital ventures. He founded Casamundo, a vacation rental platform acquired by the @Leisure Group in 2009. He later co-founded HomeToGo, which went public in 2021, and was a key investor in Finanzcheck, which was acquired by Scout24. These exits provided the financial foundation for the creation of TruVenturo and subsequent investments in emerging technologies. In 2017, Regge co-founded Apollo Health Ventures, a longevity-focused venture capital firm managing over $200 million in assets. TruVenturo continues to support early-stage tech and biotech startups through both capital and operational resources, including support from its development arm, DevelopX. The firm maintains a strong focus on digital innovation, longevity, and neuroscience-driven solutions.

Wallonie Entreprendre (WE) is the public regional promotional institution for Wallonia, Belgium, acting as an economic and financial partner for businesses at all stages—from creation, growth, transfer, to recovery. Formed in 2023 through the merger of SOGEPA, SOWALFIN, and SRIW (originally founded as SOWALFIN in 2002), WE provides equity and debt financing, loans, guarantees, and non-financial support like awareness programs and advisory services to stimulate value creation, job growth, and sustainability in Wallonia. WE targets comprehensive expertise areas including Digital & Deeptech (AI, IoT, SaaS, blockchain, medtech), Energy & Circular Transition, Growth, Social & Cooperative Economy, International expansion, Life Sciences (pharma, biotech, diagnostics, CROs/CDMOs), Industrial Policy, Site Redevelopment, Turnaround (Retournement), Health Infrastructure, and Sale & Acquisition. It ensures compliance with social/environmental standards, supports energy/digital transitions, and co-invests with private partners to foster innovation and resilience across all sectors without preference. With over €4 billion invested, including €1.9B in major holdings, €1B in SMEs via investment companies, and €1.2B in capital/loans for industrial/services, WE guarantees bank loans (e.g., €354.8M outstanding supporting 4,200 SMEs), offers unique tools like subordinated/convertible loans up to tens of millions, and drives ecosystems in life sciences, aerospace, energy, and more to attract investment and ensure business continuity.